80 results about "Gluconeogenesis" patented technology

The present invention relates to a method for producing fucosylated oligosaccharides by using a recombinant prokaryotic host cell that is cultivated on a gluconeogenic substrate, as well as to the host cell and its use. The host cell is genetically modified in that the activity of a fructose-6-phosphate converting enzyme is abolished or lowered, and the transport of the produced fucosylated oligosaccharide through the cell membrane is facilitated by an exogenous transport protein.

There is provided a composition useful for mitigating a physical burden and recovering from fatigue at the time of alcohol intake, within a safety dose of active ingredients. The composition is for accelerating alcohol metabolism and for relieving fatigue by gluconeogenesis in vivo, and is characterized by comprising an effective amount of caffeine and an effective amount of an amino acid(s) or a peptide(s) selected from the group consisting of serine, tryptophan, serine rich peptides, tryptophan rich peptides, serine / tryptophan rich peptides and mixtures thereof, as active ingredients.

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis, which is the % of glucose production that comes from gluconeogenesis (“GNG”), as opposed to glycogenolysis (“GLY”), the other form of glucose production. Nutritional formulations, materials, cocktails and methods for feeding patients by parenteral and other means are disclosed. The amount, type and rate of such nutritional feeding are typically based upon the above estimating. The invention discloses formulations that contain labels, such as deuterium, for medical diagnostics, such as for estimating BES and fractional gluconeogenesis. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

The invention relates to a non-invasive near-infrared light-controlled nano material for treating diabetes mellitus, and claims to protect the application of an up-conversion fluorescence nano material in preparation of a tool for treating diabetes mellitus. The up-conversion fluorescence nano material comprises a rare earth element doped inorganic nano material, a hepatocyte targeting molecule and a water-soluble polymer. The invention discloses a new application of the non-invasive up-conversion fluorescent nano material. An invasive optical fiber does not need to be implanted into an animalthrough an operation during diabetes treatment, near-infrared light with high tissue penetrability is used for exciting an up-conversion nano material in a living body, and light in the near-infraredband is converted into visible light through the up-conversion material so that photosensitive protein is activated, and glucose metabolism related signal pathways in cells are remotely regulated andcontrolled without relying on insulin under the condition of high time-space resolution, glycogen synthesis is promoted, glycogenesis is inhibited, and the blood glucose level is reduced.

Acetyl-L-carnitine (ALCAR) and L-carntine (LCAR) are nutraceuticals with indications in treating a variety of mental health disorders. A metabolomics-guided bioprocess method is presented to enhance ALCAR and LCAR formation in germinating plant seeds. Metabolic fluxes are manipulated by germination in bioreactors to increase oxygen availability as well as provide an aseptic environment to alter carbohydrate consumption and feedback repress gluconeogenesis. Large shifts in sunflower seed fatty acid, phospholipid and high-energy metabolism change the germination environment and these metabolic changes lead to an approximate 1000-fold increase in natural LCAR and ALCAR production by the seeds. The resulting LCAR and ALCAR products from the seeds are used for treating mental health disorders including Alzheimer's disease, geriatric depression, non-geriatric depression and schizophrenia.

The invention discloses an application of BAIBA (beta-aminoisobutyric acid) in preparation of anti-DM (diabetes mellitus) drugs. A novel treatment means is provided for preparation of the anti-DM drugs, BAIBA is applied to development of DM related drugs, and accordingly, the better DM treatment drugs are prepared. After BAIBA is delivered to a mouse with STZ / HFD (streptozocin / high fat diet) induced DM, the fasting blood-glucose level is remarkably reduced, insulin sensitivity is remarkably improved, and further, with the adoption of BAIBA, gluconeogenesis is reduced and an insulin molecular signal pathway is improved. Therefore, BAIBA can remarkably improve insulin resistance and glycometabolic disorder caused by DM, is an effective target site for DM treatment and can be taken as the novel anti-DM drug for development, and one novel pathway and means is provided for DM detection and treatment.

Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis, which is the % of glucose production that comes from gluconeogenesis (“GNG”), as opposed to glycogenolysis (“GLY”), the other form of glucose production. Nutritional formulations, materials, cocktails and methods for feeding patients by parenteral and other means are disclosed. The amount, type and rate of such nutritional feeding are typically based upon the above estimating. The invention discloses formulations that contain labels, such as deuterium, for medical diagnostics, such as for estimating BES and fractional gluconeogenesis. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.

The invention discloses an application of hederagenin and its glucoside in preparation of a medicine for inhibiting liver gluconeogenesis. The invention provides the application of the hederagenin with a sequence number being 1-15 or saponin in preparation of the medicine for inhibiting liver gluconeogenesis. The experiment result proves that the hederagenin with the sequence number being 1-15 orsaponin has obvious inhibition effect on gluconeogenesis of mice and has obvious promoting effect for synthesis of hepatic glycogen, so that the hederagenin with the sequence number being 1-15 or saponin has obvious effects for inhibiting liver gluconeogenesis. The technical staff of the filed fully believes that the hederagenin with the sequence number being 1-15 or saponin has good inhibiting effect for liver gluconeogenesis, and can be exploited to the medicines for treating diseases such as obesity, non-alcoholic fatty liver disease, and diabetes.

The invention relates to a composition having a blood sugar-lowering and lipid-lowering synergistic effect, and is used for preventing and treating hyperglycemia and hyperlipidemia. The blood sugar-lowering and lipid-lowering composition is composed of eucommia ulmoides leaves, eucommia ulmoides male flowers and cinnamon, and the adding amounts of the components comprise 50-150 parts of the eucommia ulmoides leaves, 5-25 parts of the eucommia ulmoides male flowers, and 5-50 parts of the cinnamon. Pharmacological experiments prove that the composition has the blood sugar-lowering effect, and can inhibit gluconeogenesis and promote glycometabolism simultaneously; at the same time, the composition has relatively good lipid-lowering effect. The blood sugar-lowering and lipid-lowering composition has the blood sugar-lowering and lipid-lowering effects superior to single components, and has the cooperative synergistic effect. The composition has the advantages of definite blood sugar-lowering and lipid-lowering effects, novel formulation, blood sugar-lowering and lipid-lowering synergistic effects, reliable curative effect and no obvious toxic or side effect, is a traditional Chinese medicine, also can lower blood sugar and lipid, provides a good formula, and can be used in preparation of drugs or health-care products for treating and preventing hyperglycemia and hyperlipidemia.

The invention discloses an application and construction method of a high-selenium induced insulin resistance animal model. The application and construction method comprises the following steps of: feeding 100mug / kg-200ug / kg of selenium to the stomach of an SD (Sprague Dawley) rat every day; and six weeks later, obtaining the insulin resistance animal model. According to the statistic analysis of glucose tolerance and insulin tolerance, insulin signal transduction and gluconeogenesis key enzyme test, the construction of the insulin resistance animal model by utilizing sodium selenite is feasible; and the insulin resistance animal model can be used as a high-selenium induced insulin resistance animal model and a pathogenesis and drug action mechanism research model of diabetes mellitus II. The insulin resistance rat model constructed by the application and the construction method disclosed by the invention has the advantages of simpleness in modeling method, high model establishing success rate, low cost, short period, good reproducibility and the like.

The invention discloses an application of clostridium butyrate in a preparation for prevention and treatment or adjuvant therapy of hyperglycemia and belongs to the technical field of prevention and treatment of diabetes. According to the application, during the prevention and treatment or adjuvant therapy of the hyperglycemia, butyric acid is produced in an intestinal tract, meanwhile, florae of the intestinal tract are changed, signals are sent to an ileum, a liver, a pancreatic gland and a brain by a portal vein blood sugar sensor, the ileum is promoted to secrete (GLP-1) glucagon-like peptide-1, the gluconeogenesis of the liver is lowered, pancreatic beta cells are protected, the secretion of insulin of the pancreatic gland is promoted, and thus, the action of reducing blood sugar is exerted. The clostridium butyrate is a medicine which has been proven by clinical drug trials and can be directly taken orally.

The invention discloses an application and construction method of a high-selenium induced insulin resistance animal model. The application and construction method comprises the following steps of: feeding 100mug / kg-200ug / kg of selenium to the stomach of an SD (Sprague Dawley) rat every day; and six weeks later, obtaining the insulin resistance animal model. According to the statistic analysis of glucose tolerance and insulin tolerance, insulin signal transduction and gluconeogenesis key enzyme test, the construction of the insulin resistance animal model by utilizing sodium selenite is feasible; and the insulin resistance animal model can be used as a high-selenium induced insulin resistance animal model and a pathogenesis and drug action mechanism research model of diabetes mellitus II. The insulin resistance rat model constructed by the application and the construction method disclosed by the invention has the advantages of simpleness in modeling method, high model establishing success rate, low cost, short period, good reproducibility and the like.